Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALX-101 in moderate atopic dermatitis
NCT03175354Phase 2Completed
- Sponsor
- Ralexar Therapeutics
- Start
- Apr 2017
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rovazolac in atopic dermatitis (AD) (2 arms), sponsored by Ralexar Therapeutics. Primary endpoint: Physician's Global Assessment at Day 42. Started Apr 2017; status: completed.
02
Drugs
rovazolac
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03175354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03175354.